Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

8 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Eligibility Collecting Duct Carcinoma (Kidney) NCT02363751

- 01.03.19 - 1 Formular, 2 Itemgruppen, 42 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Study of Gemcitabine+Platinium Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (BEVABEL); ODM derived from: https://clinicaltrials.gov/show/NCT02363751

Eligibility Renal Cell Carcinoma NCT00831857

- 29.09.18 - 1 Formular, 1 Itemgruppe, 13 Datenelemente, 1 Sprache
Itemgruppe: Inclusion Criteria
VEGF Imaging in Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00831857

Eligibility Renal Cell Carcinoma NCT00631371

- 29.09.18 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT00631371

Eligibility Renal Cell Carcinoma NCT00417677

- 28.09.18 - 1 Formular, 1 Itemgruppe, 19 Datenelemente, 1 Sprache
Itemgruppe: Criteria
A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00417677

Eligibility Kidney Cancer NCT00365768

- 03.10.16 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00365768

Eligibility Kidney Tumor NCT01967407 DRKS00004266

- 23.07.17 - 1 Formular, 2 Itemgruppen, 33 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Responsible Party: Johann J. Wendler, MD, Dr. med., University of Magdeburg ClinicalTrials.gov Identifier: NCT01967407 History of Changes Other Study ID Numbers: DE-UKMD-URO-001 DRKS00004266 ( Other Identifier: DRKS (German Clinical Trials Registry) ) U1111-1140-0415 ( Other Identifier: Universal Trial Number (UTN) ) DRKS00004266 ( Other Identifier: Internat. Clinical Trials Registry Platform ICTRP, WHO ) EUDAMED-No.: CIV-12-04-006021 ( Other Identifier: BfArM, German Federal Inst. for Drugs & Medical Devices ) 00020520 ( Other Identifier: DIMDI, German Inst. for Med. Documentation & Information ) Study First Received: October 15, 2013 Last Updated: November 18, 2014

Eligibility Renal Cell Carcinoma NCT00610389

- 20.09.21 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00610389

Eligibility Renal Cell Carcinoma NCT00448721

- 28.09.18 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00448721

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video